190 related articles for article (PubMed ID: 27589896)
21. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
22. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.
Harel-Dassa K; Yedgar S; Tropé CG; Davidson B; Reich R
Hum Pathol; 2017 Apr; 62():115-121. PubMed ID: 28087476
[TBL] [Abstract][Full Text] [Related]
23. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
24. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
26. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
27. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Davidson B; Doutel D; Holth A; Nymoen DA
Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
[TBL] [Abstract][Full Text] [Related]
28. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
29. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
[TBL] [Abstract][Full Text] [Related]
30. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
31. The immunohistochemical expression of CD24 and CD171 adhesion molecules in borderline ovarian tumors.
Moulla A; Miliaras D; Sioga A; Kaidoglou A; Economou L
Pol J Pathol; 2013 Oct; 64(3):180-4. PubMed ID: 24166603
[TBL] [Abstract][Full Text] [Related]
32. Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.
Haefliger S; Jain D; Menter T; Vlajnic T; Savic Prince S; Hopfer H; Mihatsch MJ; Bubendorf L
Acta Cytol; 2020; 64(6):572-576. PubMed ID: 32599592
[TBL] [Abstract][Full Text] [Related]
33. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
[TBL] [Abstract][Full Text] [Related]
34. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
[TBL] [Abstract][Full Text] [Related]
36. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
Lung; 1995; 173(2):79-87. PubMed ID: 7536281
[TBL] [Abstract][Full Text] [Related]
37. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
38. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
[TBL] [Abstract][Full Text] [Related]
40. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells.
Okamoto S; Ito K; Sasano H; Moriya T; Niikura H; Terada Y; Sato S; Okamura K; Yaegashi N
Tohoku J Exp Med; 2005 May; 206(1):31-40. PubMed ID: 15802873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
